• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

10号染色体杂合性缺失在原发性(新发)胶质母细胞瘤中比继发性胶质母细胞瘤更为广泛。

Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.

作者信息

Fujisawa H, Reis R M, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H

机构信息

International Agency for Research on Cancer, Lyon, France.

出版信息

Lab Invest. 2000 Jan;80(1):65-72. doi: 10.1038/labinvest.3780009.

DOI:10.1038/labinvest.3780009
PMID:10653004
Abstract

Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR and MDM2 amplification/overexpression, PTEN mutations, and p16 deletions, whereas secondary glioblastomas frequently contain p53 mutations. Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis. LOH#10 was detected at similar frequencies in primary (8/17; 47%) and secondary glioblastomas (7/13; 54%). The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10. In contrast, secondary glioblastomas with LOH#10 showed partial or complete loss of chromosome 10q but no loss of 10p. These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma.

摘要

胶质母细胞瘤可原发形成(原发性胶质母细胞瘤),或由低级别或间变性星形细胞瘤进展而来(继发性胶质母细胞瘤)。越来越多的证据表明,这些胶质母细胞瘤亚型通过不同的遗传途径发展。原发性胶质母细胞瘤的特征为表皮生长因子受体(EGFR)和鼠双微体2(MDM2)基因扩增/过表达、第10号染色体上的磷酸酶及张力蛋白同源物(PTEN)突变以及p16基因缺失,而继发性胶质母细胞瘤则常含有p53基因突变。第10号染色体杂合性缺失(LOH#10)是胶质母细胞瘤中最常见的基因改变;有人提出除PTEN外还有其他肿瘤抑制基因参与其中。我们使用基于聚合酶链反应(PCR)的微卫星分析对第10号染色体进行了缺失定位。在原发性胶质母细胞瘤(8/17;47%)和继发性胶质母细胞瘤(7/13;54%)中检测到LOH#10的频率相似。大多数(88%)出现LOH#10的原发性胶质母细胞瘤在所有信息性标记处均显示LOH,提示整个第10号染色体缺失。相比之下,出现LOH#10的继发性胶质母细胞瘤显示第10号染色体长臂(10q)部分或完全缺失,但短臂(10p)无缺失。这些结果与以下观点一致,即10q上的LOH是多形性胶质母细胞瘤发展的主要因素,是两种遗传途径共同的表型终点,而10p上的LOH主要局限于原发性(原发)胶质母细胞瘤。

相似文献

1
Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.10号染色体杂合性缺失在原发性(新发)胶质母细胞瘤中比继发性胶质母细胞瘤更为广泛。
Lab Invest. 2000 Jan;80(1):65-72. doi: 10.1038/labinvest.3780009.
2
Loss of heterozygosity on chromosome 19 in secondary glioblastomas.继发性胶质母细胞瘤中19号染色体杂合性缺失
J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43. doi: 10.1093/jnen/59.6.539.
3
Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.在星形细胞瘤进展过程中获得胶质母细胞瘤表型与10q25 - qter区域杂合性缺失相关。
Am J Pathol. 1999 Aug;155(2):387-94. doi: 10.1016/S0002-9440(10)65135-8.
4
PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.PTEN(MMAC1)突变在原发性胶质母细胞瘤(新发)中很常见,但在继发性胶质母细胞瘤中则不然。
J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9. doi: 10.1097/00005072-199807000-00005.
5
Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.在一部分胶质母细胞瘤中PTEN(MMAC1)肿瘤抑制基因发生突变,但在染色体臂10q缺失的脑膜瘤中未发生突变。
Cancer Res. 1998 Jan 1;58(1):29-33.
6
Molecular genetic alterations in glioblastomas with oligodendroglial component.具有少突胶质细胞成分的胶质母细胞瘤中的分子遗传学改变。
Acta Neuropathol. 2001 Apr;101(4):311-20. doi: 10.1007/s004010000258.
7
Genetic pathways to primary and secondary glioblastoma.原发性和继发性胶质母细胞瘤的遗传途径。
Am J Pathol. 2007 May;170(5):1445-53. doi: 10.2353/ajpath.2007.070011.
8
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.基于人群的星形胶质细胞瘤和少突胶质细胞瘤的发病率、生存率及基因改变的研究。
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89. doi: 10.1093/jnen/64.6.479.
9
Genetic pathways to glioblastoma: a population-based study.胶质母细胞瘤的遗传通路:一项基于人群的研究。
Cancer Res. 2004 Oct 1;64(19):6892-9. doi: 10.1158/0008-5472.CAN-04-1337.
10
Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas.在继发性胶质母细胞瘤进展过程中,22q12.3频繁出现杂合性缺失以及TIMP - 3失活。
Lab Invest. 2005 Feb;85(2):165-75. doi: 10.1038/labinvest.3700223.

引用本文的文献

1
Glioblastoma: Overview of Proteomic Investigations and Biobank Approaches for the Development of a Multidisciplinary Translational Network.胶质母细胞瘤:蛋白质组学研究及生物样本库方法概述,用于构建多学科转化网络
Cancers (Basel). 2025 Jun 26;17(13):2151. doi: 10.3390/cancers17132151.
2
Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma.胶质母细胞瘤中分子生物标志物的预测和预后意义
Biomedicines. 2024 Nov 22;12(12):2664. doi: 10.3390/biomedicines12122664.
3
Precision Population Cancer Medicine in Brain Tumors: A Potential Roadmap to Improve Outcomes and Strategize the Steps to Bring Interdisciplinary Interventions.
脑肿瘤的精准人群癌症医学:改善治疗结果及规划跨学科干预步骤的潜在路线图
Cureus. 2024 Oct 12;16(10):e71305. doi: 10.7759/cureus.71305. eCollection 2024 Oct.
4
Whole genome sequencing for metastatic mutational burden in extraskeletal myxoid chondrosarcoma.全基因组测序用于检测骨外黏液样软骨肉瘤转移灶的突变负荷
Front Mol Med. 2023 Jul 24;3:1152550. doi: 10.3389/fmmed.2023.1152550. eCollection 2023.
5
Intramedullary Spinal Cord Tumors: Whole-Genome Sequencing to Assist Management and Prognosis.脊髓髓内肿瘤:全基因组测序辅助治疗与预后评估
Cancers (Basel). 2024 Jan 18;16(2):404. doi: 10.3390/cancers16020404.
6
DUBing Primary Tumors of the Central Nervous System: Regulatory Roles of Deubiquitinases.DUBing 原发性中枢神经系统肿瘤:去泛素化酶的调控作用。
Biomolecules. 2023 Oct 10;13(10):1503. doi: 10.3390/biom13101503.
7
Photodynamic therapy and associated targeting methods for treatment of brain cancer.用于治疗脑癌的光动力疗法及相关靶向方法。
Front Pharmacol. 2023 Sep 28;14:1250699. doi: 10.3389/fphar.2023.1250699. eCollection 2023.
8
Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview.沙利度胺在胶质母细胞瘤治疗中的潜在应用:最新简要概述。
Metabolites. 2023 Apr 11;13(4):543. doi: 10.3390/metabo13040543.
9
Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?影响胶质母细胞瘤对放化疗耐药性的分子特征改变:优势何在?
Cancers (Basel). 2022 May 13;14(10):2416. doi: 10.3390/cancers14102416.
10
ADD3 Deletion in Glioblastoma Predicts Disease Status and Survival.胶质母细胞瘤中ADD3基因缺失可预测疾病状态和生存情况。
Front Oncol. 2021 Dec 14;11:717793. doi: 10.3389/fonc.2021.717793. eCollection 2021.